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Abstract 
  
	
 8 
The growing impact of nanotechnology in the field of medicine as a new 
potential clinical therapeutic agent requires the joint efforts of interdisciplinary 
research groups. 
Numerous questions must be faced. The main issues to be considered involve 
the mechanisms of interaction with the cells before, during and after their adhesion 
and internalization, the degradation pathways, cytotoxicity and the therapeutic 
efficacy. 
For these reasons, I attended to the construction of superparamagnetic iron 
oxide nanoparticles capable of providing compelling evidence of any of the above-
described key factors. To assess the utility of these nanoparticles, I chose to treat 
obesity and glioblastoma as two hyperproliferative disease models, which affect 
millions of adult every year worldwide. 
An attractive innovative possibility to approach the hyperproliferation can be 
envisaged in developing heating agents via magnetic nanoparticles. Thanks to their 
unique magnetic properties, superparamagnetic iron oxide nanoparticles now find 
large application as heating mediators for thermotherapy. 
These nanoparticles need to fulfil several criteria in order to be used as 
therapeutic agents in humans, including nontoxicity, heating efficiency and sensitivity 
of detection resulting in a capability of the nanoparticles to be confined preferentially 
at the diseased site. It is common believed in fact that alternative factors, including 
opsonisation, macrophage-mediated transport and passive delivery in general, might 
strongly affect the targeting efficiency and final destiny of nanoparticles. Using 
magnetic nanoparticles coated with protein-targeting biomarkers overexpressed by 
targeted tissue may be provided these factors.  
So the last step of the present work was focused on the construct of a peptide-
nanoconjugate to perform an accurate study of nanoparticle-membrane receptor in 
vivo. 
In summary, the general scope of this thesis was to develop an efficient 
nanoparticle for the investigation of the effect of thermotherapy mediated by 
magnetic nanoparticles on two hyperproliferative diseases. 
Several issues including nanoparticles synthesis, bio-functionalization, toxicity 
and the use as therapeutic agents have been thoroughly examinated and optimized. 
By taking advantage of the interdisciplinary view offered by synergistic chemical, 
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physical and biochemical approaches, I have designed a new nano-system suitable to 
explore new frontiers in the therapy of the hyperproliferative diseases.  
Of course, the clinical application in human treatments is the final goal of this 
and its related research. However, to reach such objective is necessary not only to 
design a suitable system for practical use, but also to assess and optimize the essential 
characteristics for specific effects such as safety, capability to get to the specific 
target, to provide useful signal amplification and to avoid the immunogenic system. 
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Introduction 
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I. Background 
Obesity and tumours have become the two major health threats in industrialized 
countries. In most cases they are strictly correlated and they influence each other. 
Among all kinds of tumour one of the most aggressive and with a poor prognosis is 
glioblastoma. 
Currently, for these pathologies there is no an efficient cure and only very 
limited progress has been made in the control of the diseases course and of the ill-
fated prognosis. Only in few cases it is possible to perform surgery and often it is not 
conclusive. Thus, the need for effective therapies is great. 
In recent years, nanoparticles have been the protagonists in biomedical research 
and in some cases they have been clinical applications. Researchers and clinicians use 
the unique chemical/ physical properties of nanomaterials for research investigation, 
for diagnosis and treatment of several otherwise untreatable diseases and for 
improving the performance of many treatments. 
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II. Adipose Tissue 
II.I. General introduction to adipose tissue 
The perception of adipose tissue has dramatically changed with the increase in 
the incidence of obesity and obesity-related comorbidities. Adipose tissue is 
increasingly being considered not simply as fat store, but as a vital and complex 
endocrine organ [1]. It shows protective, mechanical and trophic functions. 
Moreover, data support a potential role of adipose tissue in the evolution of the 
human brain, as well as in myocardial regeneration and repair [2]. 
In humans, adipose tissue is located beneath the skin (subcutaneous adipose 
tissue), around internal organs (visceral adipose tissue), in bone marrow (yellow bone 
marrow), and in breast tissue. 
Most adipose tissue consists 
of several cell types including 
adipocytes and the stromal 
vascular fraction (SVF), 
comprising preadipocytes, 
fibroblasts, vascular endothelial 
cells and a variety of immune 
cells all interspaced by a cytokine-
rich extracellular matrix and 
blood vessels [3].  
Three types of adipose tissue 
exist in humans, namely the 
brown (or plurivacuolar), the 
beige and the most common 
white (or monovacuolar) adipose 
tissue [4]. The beige adipose 
tissue is formed by beige cells which are very similar to white cells having a low basal 
expression of UCP1, but they respond to cAMP stimulation with high UCP1 
expression, reaching similar absolute levels to the brown adipocytes [6]. 
Figure 1: Localization of the major white adipose 
tissue in human body [5]. 
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 The brown fat cells are related to thermogenesis. They use the chemical energy 
of lipids and glucose to produce heat. This process is mediated by the expression of 
the mitochondrial uncoupling protein 1 (UCP1), causing the thermogenesis via 
mitochondrial uncoupling of oxidative phosphorylation of free fatty acids [7].  
Finally, the white adipose tissue is composed by highly metabolically active cells 
containing a single large lipid droplet anchored by collagen fibers forcing the nucleus 
to be squeezed into a thin rim at the periphery. Because of their metabolic function, 
these cells can directly affect the physiologic processes in neighbouring and distant 
cells by activating endocrine and paracrine pathways through an increase in secretion. 
 The most important secretions are fatty acids. In addition, several other lipid 
moieties are released by fat cells; these include prostanoids, cholesterol and retinol. 
Also a wide range of highly diverse protein factor and signalling molecules, called 
adipokines are released from adipose tissue with important roles in the regulation of 
angiogenesis, blood pressure, glucose homeostasis, lipid metabolism vascular 
haemostasis and inflammatory respons [8-9] (Figure 2).  
So, far from being an inert tissue, adipose tissue has been shown to be a super-
dynamic organ with several sophisticated functions influenced by its developmental 
origins but also by its interaction with the other organs. 
 
Figure 2: Factor secreted by adipose tissue [3]. 
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II.II. Adipose tissue’s pathology: Obesity 
Obesity represents a relevant dangerous disease to the public’s health 
industrialized countries. It is considered a high threat because it represents the major 
risk factor in the etiopathology of several other diseases (cardiovascular disease, 
hypertension, hyperlipidemia, diabetes mellitus, stroke and cancer) [10] and it is 
characterized by the expansion of adipose tissue induced by an excessive food intake 
over energy expenditure. A deeply knowledge of the mechanisms involved in the 
homeostasis of adipose tissue must be faced for developing new efficient therapies 
for obesity. 
“The growth of adipose tissue could be either due to an increase in the volume 
of adipocytes (adipose hypertrophy) or to an excess number of adipocytes 
(hyperplasia)”  (Figure 3) [11]. The hyperplasia and hypertrophy result in a 
dysregulation in circulating hormones affecting systemic energy balance. 
 
Figure 3: during overnutrition adipocytes increase in size until further expansion 
becomes limited by the matrix, which undergoes fibrotic changes [4].  
 In the adipose tissue of obese patients increase the concentration of leptin and 
decrease the production of adipokines suggesting that it could be correlated with any 
mitogenic stimuli, anti-apoptotic and pro-angiogenic effects, enhancing the cancer 
risk [12]. Also an alteration in vascular tissue development and hypoxia associated 
with macrophage infiltration is essential during expandibility of adipose tissue. As a 
consequence, the dysfunction of adipose tissue is a critical predictor of metabolic 
disorders, such as insulin resistance, hyperinsulinemia, elevated triglyceride levels, 
low HDL-cholesterol and hypertension [13,14]. 
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It is now clear how much is important to deeply known the mechanism involved 
in obesity because adipocytes exert a profound influence in neighbouring and distant 
tissues by activating endocrine and paracrine pathways through an increase in 
secretion, resulting in a real crosstalk with other tissues (Figure 4). 
 
Figure 4: adipose tissue crosstalk with other tissues [4]. 
Another important criterion in predicting diseases associated with obesity is the 
regional body distribution. “The regional body distribution of adipose tissue is at 
least as important than the total amount of body fat” [15]. For instance, 
accumulation of visceral adipose tissue is associated with insulin resistance, metabolic 
syndrome and related cardiovascular complications. Conversely, peripheral 
subcutaneous adipose tissue exhibits an independent antiatherogenic effect, which is 
not related to the obesity-pathologies. A relative simple technique to evaluate the 
total and regional adiposity in individual involves a study of the whole body with a 
scan densitometer [16].  
As currently the reduction of adipose tissue is obtained by the 
reduction/inhibition of food intake through pharmacological stimulation of the 
central nervous system or by blocking the absorption of lipids in the gut with 
however many side effects, a directly targeting of the adipose tissue could be an 
innovative strategy for obesity treatment.  
 16 
III. Nanotechnology and 
Nanomedicine 
III.I. Introduction to nanomedicine 
The ideas and concepts behind nanoscience and nanotechnology started with the 
physicist Richard Feynman on December 29, 1959, at the American Physical Society 
meeting at the California Institute of Technology with a talk entitled “There’s Plenty of 
Room at the Bottom” 
(Figure 1) describing 
a process in which 
scientists would be 
able to manipulate 
and control individual 
atoms and molecules: 
“ A biological system can 
be exceedingly small. 
Many of the cells are very 
tiny, but they are very 
active; they manufacture 
various substances; they 
walk around; they wiggle; 
and they do all kinds of 
marvellous things- all 
on the very small scale. Also they store information. Consider the possibility that we too can make a 
thing very small, which does what we want- that we can manufacture an object at that level! ”.  
At the present, nanotechnology is defined by the National Institutes of Health in 
USA as “the understanding and control of matter at dimensions of roughly 1 to 100 
nanometers”. At the nanoscale, the nanosystems own unique chemical, physical, and 
biological properties and are also very similar in scale to biological molecules and 
systems, therefore they are potentially useful for biomedical applications. 
Figure 5: Richard Feynman 
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The applications of nanotechnology to the biological systems have recently been 
referred to as “Nano medicine” by the National Institutes of Health in USA [17]. In 
particular, nanomedicine exploits the properties of nanomaterials for the diagnosis 
and treatment of diseases at the molecular level. Nanomaterials are now being 
designed to aid the transport of diagnostic or therapeutic agents through biological 
barriers, to gain access to specific functions, to mediate molecular interactions, and 
to detect molecular changes in a sensitive and highly efficient manner. Nano-
scientists created a new generation of drug delivery vehicles, contrast agents and 
diagnostic devices, some of which are currently undergoing clinical trials or have 
been approved by the Food and Drug Administration (FDA) for use in humans, 
others are in the proof-of-concept stage in research laboratories (Figure 2). 
 
Figure 6: The size of things. Nanoscale devices are one hundred to ten thousand times 
smaller than human cells [18]. 
III.II. Nanoparticles for biomedical application 
In the field of nanomedicine particular attention is given to the nanoparticles: 
particles with a well-defined chemical structure, self-organization and composition 
with sizes ranging between 1 to 100 nm [19]. They own tunable optical, electronic, 
magnetic and biological properties. In addition they can be engineered to have 
different sizes, shapes, chemical compositions, surface chemical characteristics, and 
hollow or solid structures. Nanoparticles generally consist of metal atoms, non-metal 
atoms, or a mixture of metal and non-metal atoms. The surface of nanomaterials is 
usually coated with polymers or bio recognition molecules to achieve an improved 
biocompatibility and selective binding with biological molecules and also to avoid 
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physiological defence systems (opsonization, renal clearance, etc) to optimize 
biodistribution.  
Several nanoparticles are in the clinical trial phase or have already been approved by 
the FDA for use in humans; many others are in the pre-clinical phase [20-21]. Often 
they are designed to treat pathologies otherwise non-curable and are intended for use 
either as drug carriers or as contrast agents for molecular imaging.  
Moreover these nanovehicles can also be coated with polymers, such as in primis 
with polyethylene glycol, to increase their half-life in the blood circulation, to prevent 
opsonins for adhering to the nanomaterial surface, and to reduce the rapid 
metabolism of the nanoparticulate before they reach the target tissue and avoiding 
their accumulation in other tissues. 
Another important approach is to minimize the kidney clearance. In this sense is 
fundamental to modify the physico-chemical properties of the nanoparticles to avoid 
ultrafiltration and secretion in renal nephron.  
Moreover the specific targeting allow minimizing side effects by preventing the 
nonspecific uptake of therapeutic agents from healthy tissues [22]. In addition, the 
high ratio of surface area to volume of nanoparticles favours high surface loading of 
therapeutic agents. Possible applications include drug delivery, cell targeting, multi 
modal diagnostic imaging (MRI, PET, TAC) contrast enhancement, gene therapy, 
biomarker identification, targeted hyperthermia and many others [23]. 
 
Figure 7: Potential of nanomedicine [24].  
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III.II.I. SPIONs as ‘gold standard’ in biomedicine 
Among all kinds of nanoparticles, superparamagnetic iron oxide nanoparticles 
(SPIONs) have attracted attention as interesting cargos for biomedical application 
because of their potential usefulness in oncological medicine [25] as contrast agents 
in magnetic resonance imaging and as colloidal mediators for cancer magnetic 
hyperthermia [26] thanks to their physic properties [27], biocompatibility [28], 
biodegradability [29] and facile synthesis [30]. In fact, SPIONs exhibit unique 
physical and chemical properties summarized as superparamagnetic behaviour that 
dramatically changes some of the magnetic properties [31]. Moreover, FDA has 
already approved SPIONs for use in humans; in fact the release of the iron ions 
upon dissolution can be assimilated by the body via physiological processes in their 
own metabolism. However, it remains crucial to monitor their use as therapeutic 
agents for repeated and chronic treatments [32].  
Because of their very small size, SPIONs can be administered by alternative 
routes to injection, including inhalation [33], ingestion [34], and skin penetration [35]. 
It can be assumed that they are able to interact with intracellular structures and 
modulate the physiology of the cell with external, non-invasive and harmless stimuli. 
Typically, SPIONs are composed by a magnetic core providing the specific 
properties and by a biocompatible coating that provides ample functional groups for 
conjugation of additional therapeutic moieties (Figure 3). 
 
Figure 8: schematic illustration of a full-suite SPION. The magnetic core serves as MRI 
contrast and as heat source for hyperthermia instead the polymer coating increases 
biocompatibility, reduce the uptake by immune system and allows the functionalization with 
antibody or chemotherapeutics [26].  
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III.II.II. SPIONs as heat mediators for hyperthermia  
A very innovative application of SPIONs is thermotherapy, which is considered 
a supplementary treatment associated with chemotherapy, radiotherapy and surgery 
[36]. In fact thanks to their superparamagnetic behaviour, SPIONs are able to 
produce heat when subjected to an alternating magnetic field (AMF) [37]. The origin 
of the magnetic properties lies in the orbital and spin motions of electrons, whose 
spin and angular momentum are associated with a magnetic moment. So, applying an 
external magnetic field operating at a specific frequency and power based on the 
SPIONs properties causes heat by hysteresis loss, Nèel relaxation, and induced eddy 
currents. Therefore they became available heat mediator exhibiting a sufficient 
heating capacity to achieve satisfactory temperatures in vivo without the addition of 
functional moieties. The amount of heat generated depends on the nature of 
magnetic material and of magnetic field, the frequency of oscillation and the cooling 
capacity of the blood flow in the tumour [38-39].  
It is thought that, in such a temperature range, the function of many structural 
and enzymatic proteins within cells is modified, which in turn alters cell growth and 
differentiation and can induce apoptosis. Cancer cells are sensitive to temperature 
increase and are killed when the temperature rises above 43 °C, whereas the normal 
cells can survive at higher temperature values. So, a novel hyperthermia route for 
tumours would consist of concentrating SPIONs around and inside the tumour 
tissue and making them heat through energy absorption from an external alternating 
magnetic field  (Figure 5). 
 
Figure 9: general procedure for thermotherapy. SPIONs were firstly injected into the 
human body and then an externally applied alternating magnetic field induced the 
hyperthermia [40]. 
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Superparamagnetic iron oxide nanoparticles-mediated magnetic hyperthermia 
(SMHT) seems to have advantages over conventional hyperthermic approaches 
because heat-generating nanoparticles could be prepared in colloidal suspensions 
suitable for fast injection avoiding the need for macroscopic implants. In addition, 
their distribution could potentially be controlled by different targeting strategies, and 
the particles could be made small enough to cross the biological barriers and generate 
heat very close to target tissue reducing side effects compared to traditional 
treatments. The SMHT could be performed according three strategies: arterial 
embolization hyperthermia (AEH), direct injection hyperthermia (DIH), and 
intracellular hyperthermia (IH). Their use appears as the most promising cancer 
hyperthermia therapy in particular because of the better temperature homogeneity. 
With respect to the patient’s comfort, it was found that the product Hv (where H 
is the amplitude and v the frequency of the AC magnetic field) should be lower than 
4.85 X 108 A m-1 s-1 for a treatment duration of one hour [41]. Moreover, the 
frequency has to be superior to 50 kHz for avoiding neuromuscular electro 
stimulation and lower than 10 MHz for appropriate penetration depth of the rf-field 
[42]. 
A few studies in humans using iron oxide nanoparticles as mediators of magnetic 
hyperthermia are ongoing for the treatment of colon cancer [43], prostate cancer [44] 
and for the reduction of bone tumours [45], with promising clinical outcomes. 
Clinical results showed that the combination of radiation therapy and hyperthermia 
conducted to a substantial therapeutic improvement [46]. Very recently, it has been 
demonstrated that improved efficiency could be obtained combining AMF and near-
infrared laser irradiation [47].  
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IV. Assembling a nanoplatform 
 IV.I. Chemical synthesis  
As the superparamagnetic behaviour depends on several parameters, it’s relevant 
to carefully evaluate the chemical variability to realize efficient SPIONs. In fact, the 
final size, composition, shape (spherical, rod-like, star-like, wires, octahedral, cubic 
etc.) of SPIONs depend on the salt and surfactant additives, reactant concentrations, 
reaction temperatures and solvent conditions used during their synthesis.  
Preparing monodisperse SPIONs requires the separation of nucleation step from 
the growth of nanocrystals. The “burst nucleation” event occurs at a critical 
supersaturation of the monomer concentration. The resulting nuclei grow at the 
same rate, obtaining monodisperse nanocrystals. Nevertheless these nanocrystals 
agglomerate rapidly to minimize their surface energy. Thus, a suitable capping agent 
is necessary to stabilize these nanoparticles and prevent them by forming aggregates. 
Numerous synthetic methods are used to synthesize SPIONs [48-55]. 
Among all these methods the thermal decomposition is the most used thanks to 
the possibility of obtaining SPIONs with a better-controlled size and morphology. A 
typical thermal decomposition requires the presence of a metal complex and a 
surfactant in an organic solvent with a high-boiling point. In the reaction, the 
precursors are heated up from a homogeneous mixture. In the heating up procedure, 
all the precursors are mixed and heated, so magnetic nanoparticles are made by 
tailoring reaction temperature and precursors concentration. Oleic acid is used as 
surfactant for nanoparticle stabilization and for the control of nanoparticle size and 
morphology. The metal precursors are usually metal acetylacetonates and metal 
oleates. At the end is obtained are obtained size-controlled monodisperse Fe3O4 
nanoparticles (Figure 13). 
 
Figure 10: schematic illustration of the formation of Fe3O4 nanocrystals [56].  
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IV.II. Surface modification 
Obtaining stable, biocompatible and storable SPIONs requires modifying the 
SPIONs surface. In fact in the absence of any surface coating, SPIONs have 
hydrophobic surfaces with a large surface area to volume ratio. Due to colloidal 
interactions between the particles, these particles agglomerate and form large clusters 
resulting in aggregation and precipitation. Stabilizers such as surfactants or polymers 
are usually added at the time of preparation to prevent aggregation of the nanoscale 
particulate leading to a hydrophobic surface. To make these nanoparticles 
biocompatible their surface needs to be functionalized with a surfactant addition. 
Surfactant addition is achieved by means of the adsorption of amphiphilic molecules 
that contain both a hydrophobic segment and a hydrophilic component. The 
hydrophobic segment forms a double layer structure with the original hydrocarbon 
chain anchored to the nanoparticle surface, while the hydrophilic groups are exposed 
to the outer layer of the nanoparticle, conferring it water solubility. This bifunctional 
surfactant has one functional group available for binding to the nanoparticle surface 
tightly via a strong chemical bond and the second functional group at the other end 
has a polar character so that the nanoparticle can be dispersed in water or be 
conjugated to a further molecule. 
There are various kinds of materials that can be chosen for coating 
nanoparticles: Polymer coating materials, including lipids, proteins, dendrimers, 
gelatin, dextran, chitosan and PEG [57].  
 
Figure 11: strategies for SPIONs surface modifation [58].   
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V. Aim of the work  
Currently there is no an efficient treatment for the “hyper-proliferative” diseases 
and though research remains to be done into the development of accurate therapies. 
 The aim of my PhD project was to take advantage of the efficacy of the 
magnetic hyperthermia mediated by super iron oxide nanoparticles (SPIONs) to 
enhance the targeting and the therapeutic effect of the thermotherapy against two 
“hyper-proliferative” disease cellular models: obesity and glioblastoma. 
In fact, magnetic hyperthermia mediated by magnetic nanoparticles represents a 
new promising approach, particularly for its ability to reach the targeted tissue and to 
modify the cellular behaviour avoiding side effects.  
Therefore, my PhD thesis included three chapters, in which I have described in 
more details the nanoparticles and their possible applications. 
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1.1. Introduction 
1.1.1. Magnetic hyperthermia 
Since of the pioneering work of Gilchrist et al. [1] the pursuit of innovative, 
multifunctional, efficient and safer SPIONs for magnetic hyperthermia represents a 
current challenge. Magnetic hyperthermia is based on the generation of heat via an 
alternating magnetic field (AMF) exploiting SPIONs as heating foci. In fact applying a 
specific AMF based on the SPIONs formulation causes the SPIONs to heat because 
SPIONs are able to convert electromagnetic energy into heat by hysteresis loss, Nèel 
relaxation, and induced eddy currents [2]. 
The heating ability of SPIONs subjected to an AMF is expressed as Specific 
Absorption Rate (SAR). SAR measures the rate at which energy is absorbed per unit 
mass of iron [3]. SAR values are influenced by the structure and the composition of 
the nanoparticles as well as by the concentration and the size of the nanoparticles. 
Moreover SAR changes (nanoparticles being equal) with the frequency and the 
amplitude of the magnetic field applied during the measurements [4].  
Thus, as exists physical limitation in hyperthermia application [5] it is of great 
importance to develop a SPION able to induce hyperthermia with maximum 
efficiency and minimum toxicity. 
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1.1.2. Aim of the work  
SAR values strongly depend on the chemical structure of the SPIONs. In order 
to reach the greater temperature with the minimum particles concentration is 
necessary to optimize the synthesis of the SPIONs as heating mediator avoiding 
toxicity and side effects. 
Therefore, in this chapter I present the synthesis, characterization and the study 
of the heating power of three different kinds of SPIONs specifically designed as 
magnetic fluid hyperthermia heat mediators. Starting from an iron-oleate complex we 
synthesized two different kinds of SPIONs with few modifications in the synthetic 
approach. In this way we obtained two different nanoparticles: spherical iron oxide 
nanoparticles (SIOs) and polyhedral oxide nanoparticles (PIONs).  
The first step study was focused on the heating ability of these two different 
kinds of nanoparticles to choose the more efficient for the second step in vitro in 
adipocytes. 
Alternatevely for the second study we decided to change the synthetic procedure 
of SPIONs realizing iron oxide nanocubes (IONs) as more efficient heat mediator 
for hyperthermia treatment in glioblastoma. 
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1.2. Materials and Methods 
1.2.1. Reagents 
All reageants and solvents were of analytical grade and were used without any 
further purification. Water was deionized and ultrafiltered by a Milli-Q apparatus 
(Millipore Corporation, Billerica, MA). 
For the spheric and polyhedral iron oxide nanoparticles: iron chloride (98%), 
sodium-oleate (95%), 1-octadecene (90%), oleic acid (90%), poly- (isobutylene-alt-
maleic anhydride) (85%) (Mw ≈ 6000 g mol
-1 corresponding to roughly 20 mmol of 
monomer units per polymer chain), dodecylamine (98%), tetrahydrofurane 
anhydrous 99.9%), dimethyl sulfoxide, ethanol, hexane, acetone and chloroform 
were purchased from Sigma-Aldrich.  
For the nanocubic iron oxide nanoparticles: Iron (III) acetylacetonate (99%), 
decanoic acid (99%), poly-(maleic anhydride alt-1-octadecene) and dibenzyl ether 
(99%) were purchased from Sigma-Aldrich. 
1.2.2. Synthesis of iron-oleate complex 
The iron-oleate complex was prepared by reacting iron chlorides and sodium 
oleate according to Park et al. [6]. Briefly, 1.8 g of iron chloride (FeCl3
.6H2O, 4 
mmol) and 3.65 g of sodium oleate (12 mmol) has been dissolved in a mixture 
solvent composed of 8 mL ethanol, 6 mL distilled water and 14 mL hexane. The 
resulting solution has been heated to 70°C and kept at that temperature for 4 hours. 
At the end of the reaction, the upper organic layer containing the iron-oleate 
complex was washed three times with 30 mL distilled water in a separatory funnel. 
After washing, hexane was evaporated off, resulting in iron-tri-oleate complex in a 
waxy dark red solid form (2.6 g). 
1.2.3. Synthesis of surfactant-coated spherical iron 
oxide nanoparticles (SIOs) 
Spherical iron oxide nanoparticles (SIOs) synthesis has been performed by 
solvothermal decomposition of iron tri-oleate in octadecene refluxed at 320 °C for 1 
h in the presence of oleic acid as surfactant as by Park et al [6]. Briefly, 3.6 g (4 
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mmol) of the iron-tri-oleate complex synthesized as described above and 5.7 g of 
oleic acid (20 mmol) were dissolved in 200 g of 1-octadecene at room temperature. 
The reaction mixture was heated to 320 °C with a constant heating rate of 3.3 °C 
min-1 and then kept at this temperature for 30 min. When the reaction temperature 
reached 320 °C, several reaction occurred and the initial transparent solution became 
turbid and brownish black. The resulting solution containing the nanocrystals was 
then cooled to room temperature and 50 mL of ethanol was added to the solution to 
precipitate the nanocrystals. The precipitate was washed several times with a mixture 
of hexane/acetone and the SIOs were dispersed in chloroform and stored at room 
temperature at a concentration of 10 mg mL-1. SIOs concentration has been gained 
by ICP-calibration curve (in chloroform). 
1.2.4. Synthesis of surfactant-coated polyhedral iron 
oxide nanoparticles (PIONs) with 
hyperthermic properties 
Based on the previous synthesis we decided to synthesize polyhedral iron oxide 
nanoparticles (PIONs) by a slight modified solvothermal decomposition starting 
from the iron-oleate complex. Iron-oleate (80 mmol) was dissolved in 200 g of 1-
octadecene at room temperature and 5.7 g of oleic acid (20 mmol) was added. The 
reaction mixture was heated to 110 °C for 1 h to remove solvent humidity, then 
raised to 200 °C and manteined at this temperature for additional 2 h. Next, the 
temperature was gradually raised (3°C/min) to reflux (320 °C) and refluxed for 2.5 h. 
The dark solution was finally cooled to room temperature and diluted with ethanol 
(100 mL) to precipitate the nanocrystals and centrifuged. The precipitate was washed 
several times with a mixture of hexane/acetone and the PIONs were collected and 
dispersed in chloroform and stored at room temperature at a concentration of 10 mg 
mL-1. PIONs concentration has been gained by ICP-calibration curve (in 
chloroform).  
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1.2.5. Synthesis of nanocubic iron oxide 
nanoparticles (IONs) with hyperthermic 
properties  
Based on a previous study [7] we decided to synthesize iron oxide nanocubes 
(IONs) with a diameter of 19 nm. Briefly, 0.353 g (1 mmol) of iron (III) 
acetylacetonate and 0.69 g (4 mmol) of decanoic acid were mixed in 25 mL of 
dibenzyl ether. The solution was degassed at room temperature for 45 min, then 
heated to 200°C (5°C/min) and kept at this temperature for 2.5 h. Finally, the 
temperature was increased to reflux temperature (at a rate of 10°C/min) and kept at 
this value for 1 h. After cooling to room temperature the IONs were collected by 
adding a 4-fold volume of acetone/chloroform and centrifuged at 8000 rpm. The 
sample was washed three times and at the end dispersed in 15 mL of chloroform. 
1.2.6. Polymer synthesis for water-phase transfer 
As SIOs and PIONs are hydrophobic, to transfer them in water phase we 
synthesized the amphiphilic polymer named PMA by condensation of poly 
(isobutylene-alt-maleic anhydride) with dodecylamine according to Cheng-An J. Lin 
[8]. To obtain a monodisperse polymer it is very important to carry out the reactions 
at room temperature and to use the organic solvents in anhydrous quality.  
For this synthesis, as clearly described in literature [9] we placed in a round flask 
3.084 g of poly-(isobutylene-alt-maleic anhydride) and dissolved 2.70 g of 
dodecylamine (15 mmol) in 100 mL of tetrahydrofurane.  
The two solutions were vigorously mixed together, sonicated for several seconds 
(~20 s), and heated to 55-60 °C (just below boiling point of THF) for 1 hour. 
Afterwards, the solution was pre-concentrated to about one third of the original 
volume in a rotavap system (Laborota 4000, Heidolph) under reduced pressure (p = 
200-150 mbar) in order to enhance the reaction between the polymer and the amine. 
Once the sample had been concentrated, it was left stirring overnight. Then, the 
solvent was slowly evaporated in a rotavap system until the polymer was completely 
dried. 
Finally, the PMA was re-dissolved in 25 mL anhydrous CHCl3 with a resultant 
concentration of 0.5 M monomers (= 12.5 mmol /25 mL). 
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For the functionalization of the polymer with fluoresceinamine, appropriate 
amounts of fluoresceinamine dissolved in EtOH (1 M) were slowly dropped into the 
diluted polymer solution (0.5 M) and reacted overnight under stirring. The amount of 
added molecules was calculated in such ways that between 0.25% and 4% of the 
anhydride rings of the polymer backbone were reacted. After evaporation of the 
organic solvent under reduced pressure, the polymer was re-dissolved in chloroform 
to a final concentration of 0.5 M monomers. 
For IONs we used the commercial poly-(maleic anhydride alt-1-octadecene). So 
we dissolved this polymer in CHCl3 to a final concentration of 0.5 M. 
1.2.7. Water-phase transpher 
SIOs, PIONs and IONs suspended in chloroform were transferred to water 
phase by coating them with a 0.5 M solution of the above-described polymers. The 
polymer solution and the nanoparticles were mixed for 30 min at room temperature 
(100 polymer units per nm2 of NPs surface for SIOs and PIONs and 500 polymer 
units per nm2 of NPs surface for IONs). The organic solvent was then completely 
evaporated under reduced pressure, and the solid is then resuspended in sodium 
borate buffer (SBB, 20 mM pH 12) to hydrolyze the remaining maleic anhydride 
groups of the polymer shell. 
After this phase transfer, the nanoparticles were hydrophilic and were suspended 
in water by two rounds of diluition and reconcentration through an Amicon filter (50 
kDa filter cutoff) (Millipore Corporation, Billerica, MA) concentrator tube by 
centrifuging at 3000 rpm to remove the excess unbound polymer. The resulting 
polymer-coated nanoparticles were dispersible and stable for at least 6 months in 
water phase.  
Limited to the experiments with fluourescent analysis fluoresceine amine–PMA 
(FA@PMA) was used. 
1.2.8. Particle size and surface charge analysis  
Nanoparticles hydrodynamic size and surface charge were performed using a 
Malvern Zetasized Nano ZS ZEN3600 (Worcestershire, UK) operationg at a λ of 
633 nm and a fixed scattering angle of 173°C. The sample concentration was 
adjusted to keep attenuator values between 7-9. The refractive index was 1.524. The 
measurements were performed in triplicate after dilution with MilliQ® water.  
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ζ-Potential measurements were elaborated on the same instrument equipped 
with an AQ-809 electrode soaked in 10 mM NaCl aqueous solution (pH 7.25, σ = 
14.2 mS cm–1), and data were processed by Zeta-Plus software. Sight distribution 
spectra were collected (at 23 °C) by NanoSight LM10 from NanoSight Limited 
(Amesbury, U.K.) and analyzed with NTA software. 
1.2.9. Iron quantification by ICP analysis  
The iron concentration was determined by elementary ICP-OES analysis. Briefly 
to 500 µL samples, were added 3 mL of aqua regia and, after 72 h, the samples were 
diluited with 7 mL of distilled water. All samples were measured in triplicate with 
Optima 700 DV ICP-OES (Perkin Elmer, Waltham, MA). 
1.2.10. Hyperthermic efficiency of nanoparticles 
Hyperthermic properties of nanoparticles were determined by calorimetric 
measures on sample exposed to the different AMF varying the frequency between 
110 and 521 kHz and the magnetic field amplitude in a 9-25 mT range (Magnetherm, 
NanoTherics ltd, UK). Samples were placed inside an induction coil and exposed for 
20 minutes to the AMF. The temperature variations were recorded with a 
multichannel optical fiber thermometer (Fotemp4, Optocon Systems, DE). The 
optical probe was placed slightly beneath the surface of the medium; a second one 
was placed near the induction coil and used as reference for ambient temperature. 
The thermal efficiency was expressed as SAR. 
Because it was not possible to ensure the completely adiabatic condition of the 
experimental setup, this value was determined as the initial slope of the temperature 
increase, estimated by considering the linear term of a polynomial fitting of the 
heating curve of the samples [10]: 
 
SAR= 1/me(Σcimi dT/dt) 
 
me = total mass of iron 
Ci = specific heat of different species in solution 
mi = weight of different species in solution 
dT/dt= slope of the T(t) curve 
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1.2.11. Statistical Analysis 
Data were expressed as mean ± standard deviation (SD). Data were analyzed by 
ANOVA. Post hoc analysis was carried out when statistical significance P<0.05 (*), 
and P<0.01 (**) was detected.  
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1.3. Results and Discussion 
1.3.1. Synthesis and characterization of 
superparamagnetic iron oxide nanoparticles  
Synthesizing monodisperse nanocrystals is of key importance, because the 
heating properties of the nanoparticles depend strongly on their shape and 
dimension. Here we synthesized two different kinds of monodisperse nanocrystals 
from organometallic precursors by solvothermal decomposition in octadecene with 
the aim to develop a suitable heat mediator for our study. 
According to Park et al. [6] we firstly synthesized the iron-oleate complex by 
reacting iron chloride and sodium oleate. The iron-oleate complex was then 
dissolved in 1-octadecene and slowly heated to 320° aging at that temperature for 30 
min (Figure 1). 
 
Figure 1: synthesis of iron oxide nanocrystals [6]. 
“The iron-oleate complex acts as the growth source for the synthesis. Nucleation 
occurs at 200-240 °C triggered by the dissociation of one oleate ligand from 
Fe(oleate)3 precursor by CO2 elimination. The major growth occurs at 300°C 
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iniziated by the dissociation of the remaining two oleate ligands from the iron-oleate 
species” [6]. The high temperature and the presence of stabilizing surfactants 
provided an optimal crystal nucleation and growth resulting in highly uniform and 
monodisperse nanoparticles.  
 Moreover, as clearly described by Park et al. the choice of the solvent is highly 
relevant for the particle size, which depends on the boiling point of the solvent. We 
chose 1-octadecene (b.p. 317°C) to obtain highly uniform and monodisperse 
spherical nanocrystals (SIOs).  
Unfortunately, as these nanoparticles did not shown hyperthermic properties, we 
decided to modify the procedure to obtain larger nanoparticles usable for 
hyperthermia. These nanoparticles were prepared by first keeping the iron tri-oleate 
solution in oleic acid/octadecene at 200 °C for 2 h, then gradually raising the 
temperature (3 °C/min) to reflux, refluxing for 2.5 h and finally cooling the dark 
solution to room temperature. In this way, we obtained polyhedral iron oxide 
nanocrystals (PIOs) with high SAR values. 
1.3.2. Polymer Synthesis 
An amphiphilic polymer was synthesized as coating agent according to the 
inventor Chen-An J. Lin in order to obtain water-soluble sPIONs [8]. The polymer is 
based on a poly-(maleic anhydride) backbone. This backbone represents the 
hydrophilic part, instead the hydrophobic side chains are constructed by a reaction of 
the anhydride rings with the amino-groups of dodecylamine. The concept of this 
polymer has been successfully demonstrated in several work of Parak’s group [9,11]. 
The maleic anhydride groups of the PMA backbone have been assumed to be 100 % 
reactive to primary amino-ligands through spontaneous amide linkage, which 
converts one maleic anhydride group into one corresponding amide and one free 
carboxylic acid group.  
It’s important to underline that we chose to react only the 75% of the anhydride 
rings with the amino-group of dodecylamine. The remaining 25 % of the anhydride 
rings were used in a second step for linking additional functional molecules. For 
instance, we conjugated 1% of the remaining anhydride rings with fluoresceinamine 
as organic fluorophore for the required fluorescence assays. In this way the 
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alkylamines of the fluoresceinamine can directly linked to the anhydride rings by the 
reaction of the anhydride with the amine.  
 
Figure 2: Chemical structure of the polymer. a) poly-(isobutylene-alt-maleic anhydride) 
backbone (hydrophilic part). b) dodecylamine (hydrophobic part) C) conjugation of the 
polymer with the dodecylamine. Each monomer unit comprises one anhydride ring. At the 
end we obtained an amphiphilic polymer with and hydrophilic backbone and a hydrophobic 
sidechain [9]. 
1.3.3. Water-phase transfer 
Because of their biological application, colloidal stability and water phase transfer 
of magnetic iron oxide nanoparticles are required. Thus, SPIONs were coated with 
the above-described PMA. In the coating process, the hydrophobic alkyl chains 
intercalated between those of oleic acid, which acted as surfactant, instead the 
hydrophilic backbone lend to the water solubility of the nanoparticle. So, the PMA is 
wrapped around the nanoparticles and the organic solvent is replaced by acqueous 
solution enabling the phase transfer to aqueos solution. 
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Figure 3: Scheme of the polymer coating procedure [8]. 
Upon phase transfer to water solution the remaining maleic anhydride groups of 
the polymer were hydrolyzed with Sodium Borate Buffer at pH 12 and then the 
nanoparticles were transferred to water phase to yield negatively charged carboxyl 
groups, which provide electrostatic repulsion lending to stable dispersion of 
nanoparticles.  
Phase transfer resulted in three different hydrophilic nanoparticle aqueos 
solutions: spherical shape iron oxide nanoparticles (SIOs) as determined by 
Transmission Electron Microscopy (TEM) (Figure 4A) with a diameter of 12.6 ± 0.4 
nm as measured by dynamic light scattering (DLS) (Figure 4B) and with a ζ-potential 
of –59.3 ± 2.3 mV (Figure 4C), likely suggesting a high stability of SIOs with 
minimum aggregation at physiological pH. In fact, a zeta potential value higher than 
± 30 mV is generally required for a colloidally stable nanoparticle dispersion [12].  
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Figure 4: Physical characterization of SIOs. A) Transmission electron microscopy image 
of SIOs. B) Size distribution of SIOs by DLS measure. C) Zeta Pontential Distribution of 
SIOs by Zeta-Sizer Analysis. 
We also obtained polyhedral iron oxide nanoparticles (PIONs) consisting of a 
mixture of nanocubes, truncated octahedral and irregular polyhedral as determined 
by TEM (Figure 5A) with batch-to-batch reproducibility, having an average size of 
25.1 ± 0.1 nm as detemined by DLS (Figure 5B) and a ζ−potential of –68.9 ± 4.3 
mV (Figure 5C). Also in this case, the zeta potential suggests a high stability in a 
physiological milieu. 
 
Figure 2: Physical characterization of PIONs. A) Transmission electron microscopy 
image of PIONs. B) Size distribution of PIONs by DLS measure. C) Zeta Potential 
Distribution of PIONs by Zeta Potential Analysis.  
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Figura 6: Physical characterization of IONs. A) Transmission electron microscopy of 
IONs. B) Size distribution of IONs by DLS measure. C) Zeta Potential Distribution of IONs 
by Zeta Potential Analysis. 
Alternatively  we obtained cubic iron oxide as determined by Transmission 
Electron Microscopy (TEM) (Figure 6A) with a diameter of 19.6 ± 0.4 nm as 
measured by dynamic light scattering (DLS) (Figure 6B) and with a ζ-potential of –
69.3 ± 2.3 mV (Figure 6C), likely suggesting a high stability of IONs with minimum 
aggregation at physiological pH. 
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1.3.4. Determination of the hyperthermic power of 
SPIONs in acqueos medium 
We assessed the magnetic hyperthermia (MHT) efficiency of SPIONs in aqueous 
suspension at a [Fe] of 4 mM (corresponding to ~1 mg mL–1) by varying the 
frequencies between 110 and 521 kHz and the magnetic field amplitude in a 9-25 mT 
range. While the hyperthermic efficiency of SIOs was negligible at all tested 
frequencies, PIONs exhibited frequency-dependent heat capacity with an optimal 
response at 521 KHz and 25 mT (Figure 6 A-B). Because the measurements were 
performed in non-adiabatic conditions, the curve slopes were fitted only in the first 
30 s. SAR values relative to the different conditions are summarized in Figure 6B. 
 
 
Figure 6: A) Temperature variation as a function of AMF exposure time measured on a 
sample of PIOs containing iron at a concentration of 4 mM. B) SAR values as a function of 
AMF exposure. 
Then we tested the MHT by varying the concentration between 3 and 25 mM 
(Fig. 7, A and B). The amount of heat produced by SMHT increased linearly with 
PION concentration (Fig. 7, A and B). The application of MHT to the sample 
resulted in a temperature increase of 20 °C after 120 s reaching a plateau after 6 
minutes with a maximal ΔT of 22.5 °C. 
 
Figure 7: A) temperature variation as a function of iron concentration on a sample of 
PIOs exposed to an AMF of 521 KHz and 24 mT. B) histogram representation of the 
temperature variation. 
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Therefore, our results suggested that only PIONs could provide heat capacity 
suitable for utilization as hyperthermic mediators and PIONs were thus selected for 
the biological study. Physical charatecterization and best heating curve of PIONs 
were summarized in Figure 8. 
 
Figure 3: Physical characterization of PIONs. A,B) Transmisson electron microscopy 
images of PIONs at different scaling. C) Temperature variation of AMF exposure time 
measured on a sample of PIONs containig iron at a concentration of 25 mM (MHT at 521 
KHz, 25 mT). 
Unfortunately the hyperthermic efficiency of IONs was negligible at all tested 
frequencies. This result suggests us to optimize the synthesis procedure.  
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1.4. Conclusions 
As reported in literature, not every kind of SPIONs is able to induce heat. Thus, 
slighty modifying a well-known synthetic procedure, we developed a new efficient 
nanoparticles responsive to AMF and usable for SMHT. This approach is expected 
to be of general utility and may become a universal strategy for the development of 
new efficient nanoparticles for thermotherapy. 
My results suggested that only PIONs were able to induce heat when subjected 
to an AMF and only them could provide heat capacity sufficiently suitable for the 
utilization as heating mediators in our in vitro model for adipocyte cells. Thus, for the 
first application we decided to use PIONs as heating mediators in adipocytes causing 
an impact on the adipocytes triglyceride metabolism. 
For the second study we decided to develop a nanoparticle with a better heating 
capacity, as we wanted to induce death in tumour cells. Thus, as the heating capacity 
strongly depends on the shape of the magnetic nanoparticles we decided to 
synthesize iron oxide nanocubes (IONs) as the best heating mediators for 
hyperthermia on glioblastoma. 
Unfortunately the hyperthermic efficiency of IONs was negligible at all tested 
frequencies. This result suggests us to spend more time trying to optimize the 
synthesis procedure obtaining better heating mediator. 
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Application of 
Thermotherapy to 
adipose tissue  
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2.1 Introduction 
2.1.1. Adipose Tissue Reduction 
The involvement of overweight and obesity on the pathogenesis and 
aggravation of several life-threatening diseases, including diabetes mellitus, cancer, 
cardiac and liver diseases, and of fatal events, such as stroke and myocardial 
infarction, is now well established. So there is an urgent need to develop new 
efficient treatments for the adipose tissue reduction. 
At present, the reduction of adipose tissue is obtained by different invasive and 
non-invasive techniques, including bariatric surgery, liposuction, laser, ultrasounds, 
cryolipolysis, and radiofrequency, which however do not change the energy balance 
equation and are subjected to detrimental side effects. Moreover in some cases 
these treatments require electronic devices raising the temperature in all the tissues 
exposed to heating source without any selective effect on the adipose tissue [1-3]. 
Also some pharmacological agents, including sibutramine rimonabant, are now 
withdrawn from the market, and others like amphetamine and orlistat are used in 
the management of obesity [4]. They operate like anorexizant agents on the appetite 
suppression interacting with central receptors or on the suppression of fat 
absorption by the first tract of gut. However these drugs showed limited efficacy 
and unacceptable side effects (strokes, intestinal serious side effect, kidney failure, 
severe hepatotoxicity or correlation with a higher incidence of cancer), leading to 
the withdrawn from the market or strict limitations on their use [5]. 
However little is known about the biomechanism of obesity and overweight in 
humans. These patologies result in a dysregulation in circulating hormones that 
affect systemic energy balance leading to several life-threating diseases, including 
type 2 diabetes mellitus (T2D), stroke, heart and liver disease, and enhancing the 
cancer risk [6-11]. 
Thus, understanding the molecular and cellular events regulating the 
mechanisms of hyperplasia and hypertrophy in adipose tissue is crucial to design 
rational therapies to prevent and treat obesity avoiding side effects [12].  
Adipose tissue grows by two mechanisms: hyperplasia (cell number increase) 
and hypertrophy (cell size increase) [13]. The hyperplasia and the hypertrophy in 
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adipocytes are determined by a metabolic imbalance between the triglyceride 
storage and removal referred as lipolysis. This catabolic process is precisely 
regulated through hormonal and biochemical signals that concur to the rapid 
turnover of lipids within the fat cells [14]. Lipolysis is a key of importance for the 
turnover of lipids in the fat cells; indeed a dysregulation of this turnover underlines 
several pathological conditions. The “canonical pathway” takes place in the lipid 
droplets with other co-working enzymes involved in the regulation of metabolic 
processes [15, 16]. “Canonical lipolysis” is tightly regulated via adipose triglyceride 
lipase (ATGL), the limiting-step enzyme in the triglyceride metabolism, producing 
diacylglycerol, metabolized by a hormone-sensitive lipase (HSL) into glycerol and 
fatty acids. 
  
 53 
2.1.2. Aim of the work  
Several studies proved that heat shock produces alteration in energy 
metabolism of white adipose tissue resulting in the liberation of glycerol and fatty 
acids used by other organs as energy substrates [17]. 
Even if the use of iron oxide nanoparticles as heat mediators is mainly 
dedicated to cancer thermotherapy, we reasoned that our Polyhedral Iron Oxide 
nanoparticles (PIONs) presented in Chapter 1 could be also exploited to induce a 
monitored hyperthermic effect in white adipocytes without any cellular damage or 
toxic effect.  
As our PIONs exhibited effective heat capacity in aqueos solution when 
subjected to an alternating magnetic field (AMF), the aim of the present study was 
to investigate the effect of applying intracellular superparamagnetic hyperthermic 
treatment (SMHT) in reducing the lipid content in mature adipocytes as a novel 
strategy to counteract obesity and the multiple pathologies associated.  
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2.2. Materials and Methods 
2.2.1. Cell cultures 
3T3-L1 preadipocytes (ECACC, Sigma-Aldrich, St. Louis, MO, USA) were sub 
cultured in Dulbecco’s modified Eagle’s medium nutrient mixture F12 (DMEM-
F12) containing 10% fetal bovine serum, 100 units mL–1 penicillin and 100 µg mL–1 
streptomycin in a humidified incubator at 37 °C with 5% CO2. To stimulate 
differentiation into adipocytes the cells were grown to confluency in 35x10 mm 
Petri dish and then were differentiated in accordance with a well-established 
standard adipocyte differentiation kit (3T3-L1 Differentiation Kit, Sigma-Aldrich, 
St. Louis, MO, USA). After 3-days of induction the medium was changed and the 
cells were matured in high-glucose Dulbecco’s modified Eagle’s medium containing 
10 µg mL–1 of insulin. Eight-days post-induction cells were subjected to the 
different treatments. 
2.2.2. Cell viability Assay 
The cytotoxicity of PIONs toward adipocytes was assessed by the loss of cells 
viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) 
test. Adipocytes were seeded (5 × 103 cells per well) in a 96-well plate and grown 
for 24 h in a humidified incubator at 37 °C with 5% CO2. After 24 h the medium 
was replaced with fresh medium containing different PIONs concentrations (10, 
20, 50 100 µg mL–1). After 6, 12, 24, 48 h of exposure at 37 °C, cells were washed 
with PBS 1X and then incubated for 3 h at 37 °C with 0.1 mL of 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) stock solution previously 
diluted 1:10 in DMEM-F12 medium without phenol red. After incubation, 
dimethyl sulfoxide (0.1 mL) was added to each well to solubilize the formazan. The 
absorbance in each well was read by a microplate reader (CHROMATE 4300 
Awareness Technology, USA) at a wavelength of 570 nm using a reference 
wavelength of 620 nm. 
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The test was conducted in triplicate. Statistical comparisons between treated 
and control samples were performed by using the non-parametric Mann Whitney U 
test. The cell viability (%) was calculated with the following equation: 
CV%=
ODsample
ODcontrol
× 100 
2.2.3. Flow cytometry analysis of PIONs 
internalization 
8-Days post-induction adipocytes were incubated with 10, 20 and 50 µg mL–1 
of fluoresceinamine@PIONs (FA@PIONs) at different time-points (15 min, 4, 24, 
48 h) at 37 °C with 5% CO2. After treatments, cells were washed with PBS 1X, 
detached and analyzed by flow cytometry in order to quantify the percentage of 
positive cell population. Sample acquisition (10000 events) was performed by 
Gallios Flow cytometer (Beckman Coulter Inc.) and analyzed by FlowJo Software. 
The analysis was conducted in triplicate and statistical analysis was performed by 
using the one-way Anova test. 
2.2.4. Confocal Laser Scanning Microscopy 
For Confocal Laser Scanning Microscopy, 8-days post-induction adipocytes 
were incubated with three different concentrations of FA@PIONs (10, 20, 50 µg 
mL–1) at four different time-points (15 min, 4, 24, 48 h). The culture medium was 
then removed by aspiration from the coverslips and gently washed with PBS at 
room temperature. The cells were then fixed with 4% buffered formalin for 30 min 
at room temperature. The coverslips were washed out of the formalin with PBS for 
2 minutes. For the permeabilization the coverslips were incubated in 0.5% Triton 
X-100 with PBS for 5 min. The typically adipocyte overexpression of the Glucose 
Transporter GLUT4 was marked with Antibody NBP1-49533AF647 (Novus 
Biologicals Europe, UK) labeled with AlexaFluor®647. The antibody was firstly 
diluited in BSA to a final concentration of 14 µg/mL and then the coverslips were 
incubated with the antibody for 1 h at room temperature in a dark environment. 
The coverslips were washed gently in PBS for three times 5 minutes each. The 
nuclei were then stained with HOECHST 3342 diluited in PBS to a final 
concentration of 0.2 mM. The coverslips were then inverted onto a glass slip with a 
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drop of Entellan® as mounting media. Images were obtained with Leica TCS SP5 
inverted confocal microscope (Leica). DM IRE2 confocal microscope equipped 
with an argon/krypton laser. Three laser lines were activated UV (405 nm), Visible 
(488 nm) and Visible (633 nm). A 40x objective (oil immersed, numerical aperture 
1) was used. To acquire and merge the images the Leica LAS AF software (Leica) 
was employed. Image contrast in each channel was then set using ImageJ software. 
At least 5 fields per each sample of two biological replicates were taken. 
2.2.5. SMHT treatment 
Based on the results of cell viability and the internalization test, 3T3-L1 
adipocytes were incubated for 24 h with 50 µg mL–1 of PIONs into a Petri dish. 
After 24 h the treated cells were placed inside the coil and exposed for 20 minutes 
to an AMF with a frequency of 521 KHz and strength of 25 mT. The cells were 
processed for the triglyceride quantification, glycerol content in the medium, 
ultrastructural morphology and qRT-PCR immediately after SMHT and 24 h post-
hyperthermia.  
Statistical comparisons between treated and control samples were performed 
by using the Mann Whitney U test. 
2.2.6. qRT-PCR 
Total RNA was isolated from the control and treated adipocytes using RNA-
easy Plus Mini Kit (QIAGEN; Milan, Italy). RNA (1.5 mg) was reverse transcribed 
using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems; 
Monza, Italy) and amplified using a StepOnePlus Real-Time PCR System (Applied 
Biosystems; Monza, Italy). The target cDNAs were amplified using SYBR® Green 
PCR Master Mix (Invitrogen; Monza, Italy) together with gene-specific primers for 
peroxisome proliferator-activated receptor γ, PPARγ (fwd: 
AGAGATGTGCAAACAGGGCT, rev: GCAAAGGGTTGGGTTGGTTC); 
adipsin (fwd: GTGCAGAGTGTAGTGCCTCA, rev: 
CCAACGAGGCATTCTGGGAT); adiponectin (fwd: 
ATCTGGAGGTGGGAGACCAA; rev: GGGCTATGGGTAGTTGCAGT); 
adipose triglyceride lipase, ATGL (fwd: AGAGATGTGCAAACAGGGCT, rev: 
GCAAAGGGTTGGGTTGGTTC); p53 (fwd: AAACGCTTCGAGATGTTCCG; 
rev: CTTCAGGTAGCTGGAGTGAGC); b-actin	 (fwd: 
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CATCGTGGGCCGCTCTA, rev: CACCCACATAGGAGTCCTTCTG). PCR 
conditions were 95 °C for 20 s, 95 °C for 3 s, and 60 °C for 30 s for 40 cycles. PCR 
products were measured using a StepOnePlus Real-time PCR System (Applied 
Biosystems; Monza, Italy) and relative ratios were calculated using the 2^(−ΔΔCT) 
method [18]. Data were expressed as fold changes to control. Statistical 
comparisons were performed by using the Mann Whitney U test. 
2.2.7. Transmission Electron Microscopy 
For transmission electron microscopy, the cells were fixed with 2.5% (v/v) 
glutaraldehyde and 2% (v/v) paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, 
at 4° C for 1 h, post-fixed with 1% osmium tetroxide and 1.5% potassium 
ferrocyanide at room temperature for 1 h, dehydrated with acetone and embedded 
in Epon. Ultrathin sections were stained with lead citrate and observed in a Philips 
Morgagni transmission electron microscope (FEI Company Italia Srl, Milan, Italy) 
operating at 80 kV and equipped with a Megaview II camera for digital image 
acquisition. 
2.2.8. Oil Red O staining and intracellular 
triglyceride quantification 
The degree of adipocyte differentiation and lipid accumulation of cytoplasmic 
triglycerides were detected by staining with Oil Red O (Bio-Optica, Milan, Italy). 
Briefly, the cells were washed in PBS, fixed with 4% buffered formalin for 30 min 
at room temperature. Once formalin was discarded, cells were stained for 20 min 
with 0.5 % Oil Red O solution. The nuclei were stained for 2 min with 
hematoxylin. The stained cells were photographed at 10×, 20× and 40× optical 
magnification using an Olympus microscope (BX-URA2, Olympus optical, 
GMBH, Hamburg, Germany) equipped with Image ProPlus software (Media 
Cybernetics, Rockville, USA). The triglyceride quantification was determined by 
measuring the lipid droplets content. Stained droplets were dissolved in 
isopropanol and then quantified by measuring absorbance at 490 nm with a 
VICTORTM X Series Multilabel Plate Reader. The results are shown as relative 
triglyceride content compared with the control according to Ramírez-Zacarías	et al. 
[19]. Statistical analysis was conducted by using the Mann Whitney U test. 
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2.2.9. Glycerol analysis of release of fatty acid from 
adipocytes exposed to SMHT 
The lipolytic effect of PIONs in 3T3-L1 adipocytes was determined by 
measuring the amount of glycerol released into the medium after hyperthermia 
treatment. Glycerol concentration was measured using a Glycerol Assay Kit 
(Sigma-Aldrich, St. Louis, MO, USA). In this kit, glycerol concentration is 
determined by a coupled enzyme assay involving glycerol kinase and glycerol 
phosphate oxidase, resulting in a colorimetric product (λmax= 570 nm). The 
concentration of glycerol in the samples has been determined from the standard 
curve using the equation: 
C= 
A570 sample
slope
 
C = concentration of glycerol in sample (mM); 
slope = slope determined from standard curve. 
The test was conducted in triplicate and statistical comparisons were performed 
by using the Mann Whitney U test.  
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2.3. Results and Discussion 
2.3.1. PIONs toxicity in 3T3-L1 adipocyte cells 
To test the impact of the different PIONs concentrations on cellular viability 
3T3-L1 adipocytes were incubated with 10, 20, 50 and 100 µg mL1 of PIONs in 
DMEM-F12 with 10 µg mL-1 of insulin at 37 °C for 6, 12, 24 and 48 h. MTT Assay 
monitored the extent of cellular viability. Figure 1 shows the time- and dose-
dependent decrease in cell viability. Only samples treated with 100 µg mL–1 
nanoparticles exhibited percentage of cell viability fraction lower than 80% at 6 h, 
reaching a minimum between 24 and 48 h. Therefore MTT assay suggested that 
PIONs were safe up to the concentration of 50 µg mL-1 at short and long 
incubation time, whereas 100 µg mL-1 PIONs induced a significant increase in cell 
death already after 6 h incubation.  
 
Figure 1: MTT Assay at 6, 12, 24, 48 h after PIONs uptake. **P< 0.001 vs .  untreated. 
2.3.2. PIONs uptake in 3T3-L1 adipocyte cells 
For the following experiments only PIONs concentrations safe for adipocytes 
were used. Eight days post-induction, mature adipocytes were incubated with 10, 20 
and 50 µg mL1 of dye-labeled PIONs with fluoresceinamine (FA@PIONs) in 
DMEM-F12 with 10 µg mL-1 of insulin at 37 °C for 15 min, 4, 24 and 48 h. Figure 
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2 shows time- and dose-dependent increase in uptake. Only samples treated with 50 
µg mL–1 nanoparticles exhibited labeling fraction higher than 20% at 4 h, reaching 
maximal cell labeling between 24 and 48 h.  
 
Figure 2: PIONs uptake in 3T3-L1 adipocytes. Flow cytometry analysis of FA-PIONs 
internalized by adipocytes represented as percentage of FA-positive cells compared to 
untreated cells. Histograms show a dose- and time-dependent uptake. **P < 0.01 vs . 
untreated. 
In order to confirm the internalization of PIONs in 3T3-L1-derived 
adipocytes, cells labelled for GLUT4 were incubated for 24 h at 37 °C with 10, 20, 
50 mg mL–1 of FA@PIONs, and analyzed by confocal microscopy (Figure 3). 
Images show a dose-dependent PIONs uptake, with a maximal internalization at 
the concentration of 50 µg mL–1.  
Interestingly, most of the internalized green fluorescent FA@PIONs appear as 
yellow dots due to the overlapping with the red signal of the membrane receptor 
Glut4, thus suggesting an endocytotic processes. Moreover, 50 µg mL–1 of PIONs 
did not change the expression of GLUT4 receptor, a key marker of 3T3-L1 
adipocyte differentiation, indicating that PIONs uptake did not interfere with the 
differentiation process. Moreover, confocal microscopy also reveals the safety of 
PIONs because of, once internalized, PIONs still remained confined in the 
 61 
cytoplasm, never entering the nucleus even at the longest incubation time. Entering 
the nucleus may represent a risk for the cell function, because of the possible 
interaction between PIONs and nucleic acid. 
 
Figure 3: Intracellular localization of PIONs. Confocal microscopy merged images of 
3T3-L1 adipocytes after 24 h incubation with A) 0 mg mL–1 (control), B) 10 µg mL–1, C) 20 
µg mL–1, and D) 50 µg mL–1 FA-PIONs (green). Cell membrane receptors were detected 
with the anti-Glut4 antibody (red) and nuclei were stained with Hoechst (blue). Arrows 
indicate internalized FA-PIONs (their green signal ovelaps the Glut4 red signal thus 
appearing as yellow dots).  Note the evident staining of Glut4 (overexpressed in adipocytes) 
in all samples, demonstrating that treatment does not induce dedifferentiation. 
These data were corroborated by TEM analysis (Figure 4) of adipocytes treated 
with 50 µg mL–1 PIONs at 37 °C. Ultrastructural observations demonstrated that 
PIONs were internalized via endocytosis and enclosed in endosomes (Figure 4, A 
and B): once in the cytoplasm, the PIONs were always compartmentalized into 
both endosomes (Figure 4C) and residual bodies (Figure 4D), often occurring very 
close to lipid droplets (Figure 4E). No structural cell damage was observed 
following PIONs internalization. 
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Figure 4: TEM images of PIONs uptake and intracellular distribution in 3T3-L1 
adipocytes after 24 h incubation with PIONs (50 µg mL–1). A) PIONs were internalized by 
adipocytes v ia  endocytosis (arrow) and B) compartmentalized into endosomes (arrowhead). 
C) PIONs accumulated inside many endosomes (arrowheads) ubiquitously distributed in 
the cytoplasm, D) as well as in residual bodies (asterisks) also containing heterogeneous 
cell remnants. Mitochondria (M) and endoplasmic reticulum cisternae were abundant and 
well structured, demonstrating the absence of cell damage. E) Residual bodies containing 
PIONs also occurred very close to lipid droplets (L). N: cell nucleus.  
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2.3.3. Impact of SMHT on intracellular 
distribution and cytotoxicity of PIONs in 
adipocytes 
Based on the previous results we chose to induce the SMHT treating 3T3-L1 
adipocytes 24 h with 50  µg mL-1 of PIONs incubation. The adipocytes were 
positioned in an induction coil and subjected to an AMF for 20 min (MHT at 521 
KHz, 25 mT).  
Ultrastructural analysis showed no ultrastructural cell damage immediately after 
and 24 h after SMHT (Figure 5). TEM images showed interruptions in the 
membranes of the residual bodies caused by the entrapped PIONs. This broken 
event allows their release into the cytoplasm (Figure 5A) and their accumulation 
around and even into the lipid droplets (Figure 5B). Some lipid droplets were also 
extruded from the cell suggesting a lipolytic effect (Figure 5C).  
Large amounts of PIONs were found into adipocytes until 48 h, suggesting a 
long-lasting cytoplasmic persistence. 24 h after SMHT were found only few and 
small lipid droplets in the cytoplasm. No ultrastructural cell damage was observed 
following PIONs internalization until 48 h incubation, confirming the safety of 
these nanoparticles at the concentration used (Figure 5D). 
A further advantage is that PIONs occurring in the cytoplasm are often 
enclosed in vesicular structures, i.e., endosomes formed during the endocytic 
process and residual bodies derived from the lytic pathways. These are important 
data, because a cell damage could prelude to necrotic or apoptotic processes 
responsible for inflammatory events in vivo. Moreover, since PIONs were still 
confined in the endosomes even after long incubation times the iron contained in 
PIONs never get in contact with the cytosol avoiding a potential source of 
oxidative stress [20]. 
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Figure 5: TEM images of adipocytes after PIONs-mediated SMHT. A) After 
hyperthermic treatment, some residual bodies containing PIONs appeared as damaged, 
with interruptions along their membranes (thin arrows), thus allowing the release of PIONs 
into the cytoplasm (arrowheads). B) Once free in the cytoplasm, some PIONs were found 
around and inside lipid droplets (L). C) Lipid droplets (L) approached the cell surface and 
were extruded (asterisk). D) 24 h after the hyperthermic treatment, a few lipid droplets of 
small size (L) were found in the cytoplasm, while mitochondria (M), endoplasmic reticulum 
and Golgi complexes (arrowheads) were well developed, demonstrating no cell damage and 
suggesting a high metabolic activity. N: cell nucleus. 
Accordingly, the MTT assay and the quantitative determination of tumor 
suppressor p53 mRNA expression performed on adipocytes proved the safety of 
SMHT. 
The histograms in Figure 6, A and B, show the percentage of cell viability 
under SMHT in comparison with control conditions (untreated cells subjected to 
AMF and cells treated only with PIOs but not exposed to AMF) both immediately 
after and 24 h after SMHT. No significant difference was noted in all cases 
compared to untreated cells at both time points. 
Further confirmation of the safety of our approach was derived from quantitative 
determination of tumor suppressor p53 mRNA expression in adipocytes 
immediately after and 24 h post-treatment (Figure 6, C and D, respectively). This 
experiment was mandatory to provide information about cytotoxic and mutagenic 
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effects of SMHT treatment, as an impairment of p53 gene expression normally 
affects cell growth, programmed cell death/apoptosis and cellular senescence [21]. 
Our data confirmed that neither PIONs uptake nor AMF application and the 
combination of both (SMHT) affected significantly p53 expression, which is 
particularly relevant in view of a possible clinical translation of this therapeutic 
approach. 
 
Figure 6: Effect of SMHT with PIONs on cellular viability. A) MTT assay performed 
immediately after and B) 24 h after hyperthermic treatment. The proportion of viable cells 
was referred to untreated adipocytes (100%). C) mRNA expression of p53 gene immediately 
after and D) 24 h after hyperthermia were obtained by qRT-PCR. Data were analyzed with 
the 2^(-ΔΔCT) method [18] and normalized to untreated cells.  
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2.3.4. Lipolytic effect of SMHT in 3T3-L1 mature 
adipocytes 
The effect of SMHT on the adipocyte metabolism was determined immediately 
after and 24 h after the SMHT.  
The lipolytic effect of SMHT on adipocytes was firstly assessed using a light 
microscopy after staining the cells with Oil Red O (Figure 7, A-D). The lipid 
depletion was confirmed by the significant decreased absorbance values of Oil Red 
O- extracted stain corresponding to triglycerides amount (Figure 7E), as well as by 
the concomitant increase in glycerol content in the culture medium after SMHT 
(Figure 7F). 
The absorbance of Oil Red O-extracted stain was measured by UV-vis 
spectroscopy. Eventually, to confirm the extrusion of glycerol outside the cells, we 
measured glycerol content in the medium by a colorimetric assay (Figure 7F). 
Data by microscopy examination showed the effective reduction in the lipid 
content mediated by SMHT compared to the other treatments (Figure 7, A and C). 
Further analysis of triglyceride content showed significant decrease (> 65%) of the 
lipid droplets after the SMHT treatment compared to the controls (Figure 7E). 
Furthermore, as the decrease of lipid in adipocytes is mediated by the release of 
glycerol throughout the lipid droplets in the medium, the polyol content in the 
supernatants was measured by a colorimetric assay. The analysis of the supernatants 
showed an increasing in glycerol content in the medium up to 3.5 µg mL–1 thus 
confirming its extrusion outside the cells (Figure 7F).  
As showed by electron microscopy also light microscopy (Figure 8) revealed 
low lipid content up to 24 h after SMHT in the treated adipocytes. So the SMHT 
results in a prolonged lipolytic effect. 
Beyond the evident lipolytic effect of SMHT, the results of these experiments 
suggested possible impact of this treatment on adipocyte metabolism that deserved 
more thorough investigation. 
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Figura 7: 3T3-L1 adipocytes subjected to hyperthermic treatment. SMHT hyperthermic 
treatment induces a visible reduction of lipid droplets in adipocytes (D) compared to the 
other treatment conditions, including A) control, B) PIONs without AMF, and C) AMF 
without PIONs. Intracellular lipid droplets were stained with Oil Red O and nuclei were 
stained with Eosin and visualized by light microscopy. Scale bar = 30 mm. The lipolytic 
effect was determined E) by assessment of the triglyceride content in adipocytes by fat 
extraction with isopropanol and spectrophotometric measurement of Oil Red O-stained 
adipocytes at 490 nm (data are referred to untreated sample, 100%). *P<0.01 vs .  untreated; 
^P<0.05 vs .  PIONs and AMF and F) by measuring the amount of glycerol released in the 
medium after hyperthermia treatment using a colorimetric Glycerol Assay Kit providing a 
quantitative analysis of adipocyte content. *P<0.01 vs .  untreated; ^P<0.05 vs .  PIONs and 
AMF. 
 
Figura 8: 3T3-L1 adipocytes 24 h after SMHT.Brightfield microscopy images (Oil Red 
O and hematoxylin staining) of control adipocytes (A), adipocytes incubated with PIONs 
(B), adipocytes exposed to AFM (C) and adipocytes 24h after SMHT.  
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2.3.5. SMHT effects on intracellular metabolism of 
triglycerides in 3T3-L1 adipocytes 
To start getting insight into the molecular basis of the observed SMHT-
induced lipolysis, we performed qRT-PCR analysis to assess the expression levels 
of key genes involved in lipid metabolism. We focused our attention on PPARγ and 
ATGL, as both genes play key roles in the adipolysis process [22, 23]. PPARγ 
mediates several processes among which the regulation of ATGL expression. 
ATGL is the limiting-step enzyme in the triglyceride metabolism, producing 
diacylglycerol, subsequently metabolized by hormone-sensitive lipase into glycerol 
and fatty acids. Therefore, ATGL plays a prominent role in triglyceride 
mobilization [24, 25]. In particular, due to the fact that ATGL is a key-enzyme in 
lipolysis deputed to triglycerides hydrolysis, it was investigated if the observed 
lipolytic effect observed after SMHT treatment was mediated by an overexpression 
of ATGL gene. 
 As shown in Figure 8, A and B, no significant differences were observed 
immediately after SMHT for both PPARγ and ATGL transcripts, compared with 
untreated, PIOs- and AFM-treated cells. This data also demonstrated that SMHT 
did not affect the status of cell differentiation as PPARγ is also a typical marker of 
mature adipocytes. Similar results were obtained 24 h after SMHT (Figure 7 E, F).  
Lipid metabolism is a balance between adipolysis and adipogenesis [26]. 
Adipsin is acknowledged as a critical adipokine regulating adipogenesis trough the 
regulation of the acylation stimulating protein (ASP), a key mediator of adipose 
tissue triglyceride storage [27-29]. On this basis, we sought to investigate whether 
variations in adipsin expression had occurred as a cell attempt to compensate for 
lipid depletion (lipolysis), by promoting de novo triacylglycerol storage. As shown 
in Figure 8C, neither PIONs, AMF or SMHT significantly affected adipsin 
expression in comparison to untreated adipocytes.  
These very interesting results suggested the involvement of a novel/alternative 
mechanism in the effective lipolysis observed. 
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Figura 9: Immediately Effect of SMHT with PIONs on adipocyte metabolism. Relative 
mRNA expression of atgl, pparγ , atgl target genes in 3T3-L1 adipocytes. SMHT does not 
modify the status of differentiation of adipocytes (B), and the cellular metabolism (A, C, D). 
Gene expression was analyzed by quantitative real-time PCR. Data were analyzed with the 
2-ΔΔCt method. Analysis were conducted in triplicate and statistical analysis were 
performed using the Mann Whitney U test. No signficant differences were found. 
 
 
 
Figura 10: Effect of SMHT with PIONs 24 h after on adipocyte metabolism. Relative 
mRNA expression of pparγ , atgl target genes in 3T3-L1 adipocytes. SMHT does not modify 
the status of differentiation of adipocytes (A), and the cellular metabolism (B). Gene 
expression was analyzed by quantitative real-time PCR. Data were analyzed with the 2-
ΔΔCt method. Analysis were conducted in triplicate and statistical analysis were performed 
using the Mann Whitney U test. No signficant differences were found.  
A B 
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2.4. Conclusions 
Most life-threatening human pathologies, including cancer, diabetes mellitus, 
cardiovascular dysfunctions, and chronic inflammatory disorders are directly or 
indirectly caused by or associated to excess body weight. Thus, there is an urgent 
need to find out new solutions to rapidly and efficiently reduce the lipid 
components of adipose tissue using safe and physiologically mild approaches 
combined with healthy and balanced diet. 
The results of our study suggested that targeting the energy storage of white 
adipose tissue with SMHT might be used as an innovative anti-obesity strategy 
promoving an anti-adipogenic effect.  
The modulation of cellular metabolism in adipocytes takes advantage of the 
hyperthermic property of superparamagnetic iron oxide nanoparticles. Here we 
show that colloidally stable PIONs endowed with good heat capacity were taken up 
by mature adipocytes and released from endosomal compartmentalization into the 
cytoplasm upon application of an AMF, which results in PIONs accumulation in 
close proximity of lipid droplets. Free PIONs seem to preferentially migrate close 
to and even inside lipid droplets: this preference could be associated to the 
amphiphilic character of nanoparticle coating. SMHT triggers the disintegration of 
large lipid stores into minute droplets activating the metabolic function of the cell, 
which makes the metabolism and removal of triglycerides highly effective. This 
phenomenon does not induce cell damage probably because residual bodies do not 
contain lytic enzymes and/or membrane integrity is rapidly restored, similarly to the 
process of endosomal escape [30].  
 Interestingly, the observed lipolytic process is not accompanied by increased 
expression of ATGL, whose mRNA expression is normally elevated by peroxisome 
proliferator-activated receptor (PPARγ) agonists. This suggests that a pathway 
involving other than PPARγ and ATGL effectors may be involved in the lipolysis 
effect by SMHT and yet to be defined. Alternatively, one can hypothesize the 
occurrence of a “thermal stimulus” responsible for lipid extrusion to be further 
investigated. Moreover, mRNA expression of adipsin, the major adipokine released 
by adipose cells promoting triglyceride storage in adipocytes, was not upregulated 
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as a means to counteract the significant lipid loss, thus establishing a possible 
correlation with the prolonged (24 h) delipidated state of the SMHT-treated 
adipocytes. The latter observation further argues in favor of a lipolytic mechanism 
independent of the “canonical” events regulating the process. 
This particular delipidation process has been recently investigated in detail in 
human adipocytes: it is an active process triggered by cell stress, and lipid droplets 
are extruded through micropores transitory forming in the plasmalemma, thus 
allowing cell structural preservation and viability [31].  
Accordingly, adipocytes subjected to SMHT not only remain fully vital up to 24 
h post-treatment, but also show well-preserved ultrastructural features and 
unaltered expression of genes involved in lipid metabolism and in cell 
differentiation process. This result is promising in view of the fundamental role of 
adipocyte differentiation in maintaining the cell commitment, preventing 
transcription and translation error rates and undesired signal deletions that increase 
the risk of neoplastic degenerations associated to obesity management. 
Notably, the treatment results in a significant delipidation persisting, for at least 
24 h, in the absence of cell death, damage or dedifferentiation. The biological 
reasons of such a rapid and massive lipolytic effect remain unclear. However our 
results clearly demonstrated that under controlled applied conditions SMHT can act 
as a mild controlled stress able to efficiently activate a physiological lipolytic 
process.  
The success of this pioneering approach in vitro opens promising perspectives 
for the application of SMHT in vivo as an innovative safe and physiological mild 
approach against obesity. In view of a possible future translation of this therapeutic 
approach, we envisage that the effect of SMHT treatment of adipocytes might 
impact adipose hypertrophy and hyperplasia in overweight subjects thus affecting 
adipose tissue dysfunction and contributing in the prevention of cancer, T2D and 
cardiovascular diseases.  
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Application of 
Thermotherapy to 
Glioblastoma  
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3.1 Introduction 
3.1.1. Glioblastoma 
“Gliomas are the most common type of primary brain tumour and are often fast 
growing with a poor prognosis for the patient. Their complex cellular composition, 
diffuse invasiveness and capacity to escape therapies has challenged researchers for 
decades and hampered progress towards an effective treatment” [1].  
According to the World Health Organization system of classification and 
grading, Glioblastoma represents the most anaplastic tumour of astrocytic lineage-
astrocytoma grade IV [2]. It is the most common and most aggressive, showing 
vascular endothelial proliferation, necrosis and very high cell density and atipias. Also 
the characterization of the distinct molecular genetic markers associated with the 
tumour has provided subclasses of glioma to be identified based on a molecular 
signature or gene expression patterns. This sub-classification allows the correlation 
of treatment effects or prognosis with molecular markers, so that patients can be 
more effectively selected for more appropriate therapies. The sub-classification has 
also contributed to the more detailed elucidation of components of molecular 
oncogenic pathways. For example which oncogenes are activated, such as the growth 
factor receptor (EGFR) involved with the migration of glioma cells throughout the 
central nervous system. 
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It is also important to underline the presence of the glioma stem cells, which are 
responsible for maintaining these tumours after therapy and repopulating tumours 
after gross total resection. These cells express markers that can be used to identify 
the cells that are capable of tumour formation when xenotransplanted and have a 
capacity for self renewal, clonogenicity and differentiation into a broad range of cell 
types. The most important marker of the cancer stem cell is the CD133 [3].  
 
 
Figure 1: Stem cell differentiation and tumorigenesis [1]. 
3.1.2 SPIONs as contrast agents in MRI 
The use of SPIONs as contrast agents for MRI was associated with substantial 
increases in diagnostic sensitivity and specificity [4]. The aim of their use is 
visualizing molecular characteristics of physiological or pathological processes in 
living organisms before they manifest in form of anatomic changes. 
 MRI offers several advantages over alternative techniques, including lack of 
irradiation, possibility to generate 3D images, excellent spatial resolution with 
optimal contrast within soft tissues and a very good signal-to-noise ratio. 
Paramagnetic (e.g. gadolinium) and superparamagnetic (e.g. SPIONs) compounds 
can be used as MR contrast agents. While the paramagnetic species enhance the 
signal in T1-weighted images resulting in positive contrast, magnetic nanoparticles 
provide strong signal enhancement in T2-weighted images (negative contrast), owing 
to a different contrast mechanism [5]. 
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Contrast agents may be used for identifying specific biomarkers. Ideally, the 
biomarkers should be abundantly and only expressed on the desired cell types. 
Furthermore, disease-specific biomarkers should be clearly different form healthy 
status. To identify the specific biomarker SPIONs would be composed of two 
components: 1) the magnetic iron oxide core represents the imaging component and 
2) the attached molecules represent the targeting or affinity component.. 
In case of tumours a contrast can be observed between tissues with and those 
without having captured superparamagnetic iron oxide nanoparticles, owing to a 
difference in the precession frequency of water protons in proximity of paramagnetic 
nanodipoles (Figure 11). 
 
Figure 2: iron oxide nanoparticles for early detection of cancer [6]. 
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3.1.3. SPIONs as theranostic agents 
“Theranostic” is defined as the capacity of combining diagnosis and therapy into 
a single agent [7]. “Theranostic agents” allow obtaining more specificity and more 
sensibility in the therapeutic diagnosis and prognosis.  
Nanotechnology has offered an unprecedented opportunity to design 
“nanotheranostic agents” that can act as therapeutic and contrast agent combining 
therapy and diagnosis. These nanoparticles possess unique optical or magnetic 
properties that could be combined with the loading of therapeutic agents allowing 
for the conjugation of a second or third functionality, a feature that encourages the 
formation of an all-in-one nanosystems with comprehensive features. 
 
Figure 3: Application of theranostic nanomedicine formulation [7].  
 
3.1.4. Targeting nanoparticles 
The real challenge in nanomedicine is represented by the possibility of realizing a 
therapeutic agent with maximum specificity and sensibility. It means develop a 
nanoparticle capable of recognizing the sick site showing its effect preferentially in 
this site with a real reduction of side effects. For this purpose designing suitable 
functionalized nanoparticles is a general procedure claim.  
To increase to probability of achieving the target the first requirement is a long-
circulating effect. As the macrophages recognize the nanoparticles as “hosts” and 
remove them from the blood circulation is necessary to realize macrophage-evading 
nanoparticles. Furthermore, long-circulating particles escape from macrophages 
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could accumulate where the capillaries have open fenestrations and vascular 
abnormalities such as in tumour or in obesity cases where the endothelial barrier is 
perturbed by inflammatory or other processes. 
The design of such “stealth ” nanoparticles requires the consideration of a 
multitude of physico-chemical and physiological factors, affecting circulation time 
[8]. 
Generally the surface protection by a barrier of hydrophilic groups prevents the 
opsonin adsorption and therefore avoids the macrophage recognition. Among 
several molecules, linear dextrans, Polyethylene glycol (PEG) and their derivates are 
widely used in order to improve the circulation lifetime and bioavailability and 
decrease their immunogenicity, renal clearance rate and dosing frequency. PEG has 
been shown to be the most effective polymer for suppressing protein adsorption. It 
is the α,ω−dihydroxyl derivate of polyethylene oxide and is a flexible polymer, 
hydrophilic (but also soluble in some organic media), not biodegradable and easily 
excreted from living organisms by physiological routes. The optimal molecular 
weight varying between 2000 and 5000 Da and its functional end-groups are available 
for derivatization leading to numerous possibilities for covalent attachment. 
 
Figure 4: macromolecules used as hydrophilic coating for monuclear phagocyte system-
evading nanoparticles [9]. 
Ligand conjugation is the second requirement for active targeting. To enhance 
the capability of long-circulating nanoparticles to be uptaken from target cells , the 
surface of nanoparticles has to be modified with ligands that specifically bind to the 
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receptors present on the target cells, by molecular recognition processes involving 
antibody-antigene interactions. Among these ligands, often recurring are 
oligosaccharides, oligopeptides, folic acid, antibodies and their fragments. 
Due to the unique specificity of monoclonal antibodies for their molecular 
counterparts and to the possibility to produce immunoglobulins for almost every 
known marker receptor, this class of proteins is usually considered the preferred 
choice for active targeting and great effort has been devoted to the development of 
antibody-functionalized nanocarriers. 
Therefore, for tumour targeting, folic acid, antibodies or peptides could be 
grafted to PEGylated nanoparticles in order to take advantage of the frequent 
overexpression of the specific receptors onto the surface of human cancer cells. 
Interestingly, nanoparticles conjugated with antibodies appeared to interact more 
efficiently with their receptors than free antibodies.  
However, antibody coupling has at least two drawbacks: 1) the overall size of the 
antibodies (typically into the range 15-20 nm), which cause particles to diffuse poorly 
through biological barriers, and 2) their immunogenicity, i.e. the property of being 
able to elicit an immune response within an organism.  
For this reason, the coupling of small non-immunogenic ligands to polymeric 
carriers has been also investigated. 
3.1.5. GE11 Peptide 
Targeting may be essential for efficiency mediated cell-binding of shielded 
nanoparticles and enhanced nanoparticles uptake by receptor-mediated endocytosis 
or related uptake pathways.  
Epidermal growth factor (ErbB1, EGFR) is a typical receptor used for targeting 
tumour cells and is overexpressed by glioblastoma cells. Various EGFR binding 
molecules have been explored as targeting ligands, including recombinant EGF 
protein, EGFR binding antibodies and peptides. Among all these ligands the 
enriched phage clone encoding the amino acid sequence YHWYGYTPQNVI 
(designated as GE11) was described as the best efficient. “Competitive binding assay 
and Scatchard analysis revealed that GE11 peptide bound specifically and efficiently 
to EGFR with a dissociation constant of 22 nM, but with much lower mitogenic 
activity than with EGF. The peptides were internalized preferentially into EGFR 
highly expressing cells, and they accumulated in EGFR overexpressing tumor 
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xenografts after i.v. delivery in vivo. In conclusion GE11 is a potentially safe and 
efficient targeting moiety for selective drug delivery systems mediated through EGF” 
[10]. 
The PEGylation reduces the complement activation (innate immune system), 
improves solubility, reduces the interaction with blood cells and serum proteins, 
provides a better biocompatibility and prolongs blood circulation times [11]. 
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3.1.6. Aim of the work  
Currently there is no an efficient cure and only very limited progress has been 
made in the control of the glioblastoma course. Thus, the need for effective therapies 
is great. In particular this involves the drug delivery across the blood-brain barrier. 
Beyond molecular targeting of a specific cellular signalling pathway, more complex 
tumour-associated processes such as cell migration, immunosuppression or 
angiogenesis could also be targeted. 
Several studies proved that heat shock produces apoptosis on cancer cells 
resulting in tumour reduction. 
Even if the use of my previous PIOs was mainly dedicated to adipose tissue, I 
reasoned that changing the synthesis procedure could be also exploited to obtain a 
more efficient heating mediator and to induce a hyperthermic effect in glioblastoma 
cells as described in Chapter 1. 
The aim of the present study was to investigate the effect of applying 
intracellular superparamagnetic hyperthermic treatment (SMHT) in reducing the 
mass tumour as a novel strategy to counteract glioblastoma and the cell migration. 
It is worth noting that, similarly to many other nanoparticles, SPIONs surface 
may be functionalized and their distribution controlled by targeting strategies, thus 
focusing the hyperthermic treatment preferentially in the unhealthy cells. 
So I decided to functionalize IONs with the GE11 peptide targeting EGF 
receptor of glioblastoma cell line to have an active targeting so to induce the 
thermotherapy preferentially on the cancer cells reducing side effects. In fact for 
glioblastoma targeting GE11-PEG12NH2 peptide has been shown to mediate 
sequence-specific binding of model nanoparticles to EGFR expressing cells and 
remarkably increased uptake activity. 
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3.2. Materials and Methods 
3.2.1. Cell cultures 
U87-MG cell line (purchased by ATCC Manassas, VA), was cultured in Eagle’s 
Minimum Essential Medium (EMEM) with 10% of Fetal Bovine Serum (FBS), 1% 
of a mix of penicillin/streptomycin 1:1 and 1% of L-glutamine 200 mM, in 25 cm2 
plates and incubated at 37°C in humidified air with 5% CO2. Medium and L-
glutamine were purchased by Sigma-Aldrich (Italy), while serum and antibiotic mix 
were acquired by GIBCO Life Technologies (USA). When at confluence, cells were 
treated with trypsin-EDTA 1% (GIBCO Life Technologies, USA), harvested and 
centrifuged at 1200 rpm for 5 min. The supernatant was discarded and cells pellet 
was resuspended in 1 ml of complete medium, placed in 75 cm2 plates and incubated 
at 37°C and 5% of CO2 until 80% confluence was detectable. EGFR expression in 
U87MG cells was determined using flow cytometer FACSCanto (BD biosciences) 
with a primary anti-EGFR antibody and an anti- FITC antibody secondary 
(millipore). 
3.2.2. GE11 Solid-phase Synthesis 
GE11-PEG12NH2 peptide is generated by standard Fmoc-Solid phase assisted 
synthesis (SPS). SPS offers a way to synthesize precisely defined oligomer structures. 
The SPS can be carried out manually with an overhead shaker using microreactors 
with polyethylene filters for vacuum filtration. The amount of resin depends on the 
determined resin loading and of the scale size (1/L [mmol/g] x scale size [mmol] = 
resin amount [g]). Approximately 10 µmol of resin correlate with approximately 20 
mg of yield. 
I always followed a repetitive synthesis cycle: 
• Coupling (60 min). 
• Washing (3× DMF, 3× DCM). 
• Kaiser’s Test (1). 
• Deprotection (2). 
• Washing (3× DMF, 3× DCM). 
• Kaiser’s Test. 
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A 2-chlorotrityl chloride resin is used as solid support. The Resin was firstly 
loaded in a syringe reactor and swelled with DCM for 20 min. Coupling of the Fmoc 
protected amino acids is performed with a fourfold excess (based on the quantity of 
free amines) whilst an identical excess of HOBt and PyBOP is used for preactivation. 
DIPEA is added with an eightfold excess (also related to free amines). HOBt and 
PyBOP are dissolved in 5 mL of DMF/g of resin and the (artificial) amino acids are 
dissolved in 5 mL of DCM/g of resin. The corresponding amount of DIPEA is 
added, the solutions are mixed for preactivation and added to the resin.  
Coupling, as well as deprotection are verified by testing for free amines 
qualitatively using Kaiser’s test. If the result is unsatisfying the previous coupling or 
deprotection step is repeated.  
For the GE11PEG12NH2 I followed this procedure: 
1. Considering resin loading and desired synthesis scale size, take the required 
amount of preloaded 2-chlorotritylchloride resin and transfer into the 
corresponding reactor. 
2. Swell the resin for 30 min with 10 mg/mL DCM. 
3. Synthesize the GE11 peptide by sequential coupling and deprotection of Fmoc-
L-Ile-OH, continue with Fmoc-Val-OH, Fmoc-L-Asn(Trt)-OH, Fmoc-L-
Gln(Trt)-OH, Fmoc-L-Pro-OH, Fmoc-L-(Thr)-tBu-OH, Fmoc-Tyr(tBu)-OH, 
Fmoc-L-Gly-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Trp(BOC)-OH, Fmoc-L-His(Trt)-
OH and end with Fmoc-Tyr (t-Bu)-OH. 
4. Continue with the synthesis at the free amine by coupling Fmoc-dPEG12-NH2 
using the standard coupling conditions. 
5. Dry the peptide on high vacuum for 30 min 
6. Prepare a clevage cocktail (3) for cleaving the resin from the acid labile linker 
7. Apply 10 mg/mL of cleavage solution to resin for 90 min at RT and collect it 
afterwards. 
8. The resin is washed afterwards three times with 10 mg/mL resin of TFA. 
9. Allow the combined solutions to evaporate to 1mL and to precipitate in a 
dropwise manner into a 50 mL of ice cold precipitating solution (4). 
10. Centrifuge for 20 min (4000 g, 4°C), discard the supernanant and dry the 
precipitate under nitrogen (N2) stream. 
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11. Dissolve the obtained product in size exclusion running buffer and purify it by 
Size Exclusion Chromatography (SEC). 
12. Take the product containing fractions, and pool them into a tared 15 mL tube, 
then snap freeze and lyophilize. 
The GE11PEG12NH2 peptide were purified with Sephadex G10 size exclusion 
chromatography (SEC) medium and characterized with MALDI_TOFL instrument. 
At the end the obtained HCl salt of the oligomer was stored at -20 °C. 
Fmoc and Boc-protected α-amino acids were purchased from Iris Biotech, 
Marktredwitz, Germany) and Fmoc-N-amido-dPEG12-NH2 from Quanta 
Biodesign, Powell, Ohio, USA. DCM, N,N-Dimethylformamide (DMF), DIPEA. 1-
Hydroxybenzotriazole (HOBt). Benzotriazol-1-yl-oxy tripyrrolidinophosphonium 
hexafluorophosphate (Pybop®) were purchased from Multisyntech GmbH, Witten, 
Germany. 
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3.3. Results and Discussion 
Taking the advantage of the SPS I obtained a novel GE11-PEG12NH2 oligomer 
charatecterized by a well-defined chemical structure as described in Figure 5.  
 
 
Figure 5: Chemical structure of GE11 peptide conjugated with PEG12NH2.  
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The high yield of the synthesis and the purity of the obtained oligomer were 
confirmed by Mass Spectroscopy (Figure 6). The final molecular weight of the above 
described GE11PEG12NH2 oligomer was determined as 2141,3 Da. 
 
Figure 6: Mass Spectrum of GE11-PEG12NH2.  
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3.4. Conclusions 
Nowadays the need for an efficient therapy of the glioblastoma disease is great. 
The prognosis for the patients with glioblastoma is always poor and the treatments 
are ineffective and often very toxic. 
Thus, there is an urgent need to find out new solutions to rapidly and efficiently 
reduce the tumour mass using safe specific and physiologically mild approaches. 
Thermotherapy was described as a very innovative and efficient treatment that colud 
be combined with surgery. However is necessary to develop a suitable, stable and 
efficient heating mediator. 
Unfortunately, as described in Chapter 1 IONs obtained until now need to be 
optimized realizing a best efficient heating mediator. 
However, the result of the SPS suggested that once obtained suitable IONs, they 
could be immediately functionalized with the GE11 peptide realizing an active 
targeting thermotherapy for glioblastoma. In fact the glioblastoma cells were 95% 
positive for the EGF receptor and the GE11 peptide is the best ligand for this 
receptor. 
This approach might be used as an innovative anti-glioblastoma strategy. The 
death of the glioblastoma cells might take advantage of the hyperthermic property of 
superparamagnetic iron oxide nanoparticles hypothesizing a “thermal stimuls” 
responsible of the “killing effect”. 
Notably, the studies described in literature, the promising thermotherapy effect 
and the need of realizing an efficient therapy suggest continuing with the synthesis 
optimization of the IONs, with the functionalization with the GE11 peptide 
targeting selectively the glioblastoma cell line.  
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3.6. Notes 
(1) The Kaiser’s test solutions is based on 80% (w/v) phenol in EtOH; 5% (w/v) 
ninhydrin in EtOH; KCN/pyridine (2 mL of 1 mM KCN in 98 mL of pyridine). 2% 
1 mM KCN (v/v) in pyridine. 
(2) Fmoc-deprotection solution is composed of 20% (v/v) piperidine/DMF.The 
Capping solution: 80/15/5 (v/v/v) DCM/MeOH/DIPEA. 
(3) The Cleavage cocktail: 95/2.5/2.5 (v/v/v) trifluoro acetic acid 
(TFA)/triisopropylsilane (TIS)/dH2O. 
(4) The Precipitating solution: 1/1 (v/v) methyl tert-butyl ether (MTBE)/n-hexane. 
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General Conclusions  
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During my PhD I have studied the therapeutic potential of Hyperthermia 
mediated by SPIONs in two different in vitro cellular models of two relevant 
hyperproliferative diseases: 3T3-L1 adipocytes for obesity (Chapter 2) and U87-MG 
for Glioblastoma (Chapter 3). 
Given the nanostructure of these SPIONs, there is a broad range of options in 
their construction and functionalization of their surface, which makes it possible to 
endow them with multiple and specific properties.  
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However the efficacy and safety of nanoconstructs must be preserved and 
validated by in vitro studies in order to avoid side effects, in view of the development 
of therapeutic approaches. 
Based on these considerations, in the present thesis I have taken advantage of 
SMHT to address the following issues of biomedical relevance: 
• In Chapter 1 I have presented the possibility to synthesize efficient SPIONs as 
heating mediator. My results suggested that only one type of SPIONs, namely 
PIONs, were able to induce heat when subjected to AMF and only them could 
provide heat capacity sufficiently suitable for the utilization as heating mediators 
in our in vitro model. These PIOs were stable in physiological milieu for at least 6 
months and were covered by an amphiphilic polymer realizing nanoparticles that 
could be functionalized with peptides for active targeting. 
• In Chapter 2, I have carried on in vitro studies on adipocyte cell line, using 
PIONs as heating mediators whereby SMHT causes an impact on the adipocytes 
triglyceride metabolism. The results of our study suggested that targeting the 
energy storage of white adipose tissue with SMHT might be used as an 
innovative anti-obesity strategy promoving an anti-adipogenic effect. Notably, 
the treatment results in a significant delipidation persisting, for at least 24 h, in 
the absence of cell death, damage or dedifferentiation. The biological reasons of 
such a rapid and massive lipolytic effect remain unclear. 
• In Chapter 3, I have presented the SMHT application on glioblastoma cell line. 
This study is very preliminar so I could only show the perspective of this 
application. In the first step I tried to synthesyze a more efficient SPIONs-
heating mediator, but the bad heating results suggested to optimize the synthesis 
procedure. However I realized a very efficient oligomer characterized by the 
sequence GE11PEG12NH2 as targeting agent for the glioblastoma cell line. Once 
obtained the suitable IONs they could be immediately functionalized with the 
GE11 oligomer realizing an active targeting thermotherapy for glioblastoma. In 
fact the glioblastoma cells were 95% positive for the EGF receptor and the 
GE11 peptide is the best ligand for this receptor. This approach might be used 
as an innovative anti-glioblastoma strategy. The death of the glioblastoma cells 
might take advantage of the hyperthermic property of superparamagnetic iron 
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oxide nanoparticles hypothesizing a “thermal stimuls” responsible of the “killing 
effect”. 
In conclusion, we were able to produce very promising heating mediator for 
SMHT with high efficiency of heating, stability and good safety for the surrounding 
microenvironment of therapeutic agents in case of adipocyte cell line. The success of 
this pioneering approach in vitro opens promising perspectives for the application of 
SMHT in vivo as an innovative safe and physiological mild approach against obesity 
and the studies described in literature, the promising thermotherapy effect and the 
need of realizing an efficient therapy suggested us to continue with the synthesis 
optimization of the IONs, with the functionalization with the GE11 peptide 
targeting selectively the glioblastoma tumour. 
